Sangamo ex vivo treatment increases resistance to HIV/AIDS infection
This article was originally published in Scrip
Executive Summary
Exciting news from the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): a Californian biotech company has demonstrated that a drug-like non-vaccine treatment of immune cells from HIV/AIDS patient can be used to confer resistance to HIV/AIDS infection to patients previously not resistance to the virus, and that resistance can enable patients to reduce viral load to undetectable levels even in the absence of other anti-retroviral therapy.